Economics of Sickle Cell Disease and Evidence to Support Comprehensive Care

Alecia Nero; Janis Bozzo

doi:10.1016/j.hoc.2022.07.013

Economics of Sickle Cell Disease and Evidence to Support Comprehensive Care

Hematol Oncol Clin North Am. 2022 Dec;36(6):1125-1135. doi: 10.1016/j.hoc.2022.07.013.

Authors

Alecia Nero¹, Janis Bozzo²

Affiliations

¹ Department of Internal Medicine, Division of Hematology-Oncology, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9255, USA. Electronic address: alecia.nero@utsouthwestern.edu.
² Financial Planning and Analysis, Yale New Haven Health, 789 Howard Avenue, New Haven, CT 06519, USA.

PMID: 36400534
DOI: 10.1016/j.hoc.2022.07.013

Abstract

Sickle cell disease (SCD) is a serious blood disorder leading to complex care needs. Comprehensive, multidisciplinary programs are ideally suited to deliver patient-centered care and address other relevant social determinants of health. Patients with SCD face many inequities in health care, further reinforcing the need for comprehensive care models to address these relevant issues. Comprehensive care models can be financially advantageous to institutions that care for vulnerable patients with SCD while simultaneously increasing care quality.

Keywords: Comprehensive sickle cell care; Cost of care; Health care economics; Sickle cell disease.

Publication types

Review

MeSH terms

Anemia, Sickle Cell* / therapy
Comprehensive Health Care
Humans
Patient-Centered Care